Search clinical trials for: Olodaterol (BI 1744) very low

Total 304 results

Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

Pulmonary Disease, Chronic Obstructive

United States, China, Germany, Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study in Healthy People to Measure the Amount of BI 655130 in the Blood After Injecting Different Doses Into Different Parts of the Body

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
University of Texas at Austin

Completed

Effect of Daily Steps on Fat Metabolism

Atherosclerosis | Metabolic Syndrome

United States
University of North Carolina, Chapel Hill
Takeda Pharmaceuticals North America, Inc.

Completed

Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease

Overweight | Gastroesophageal Reflux Disease | Acid Reflux Disease

United States
Hartford Hospital

Not yet recruiting

Acceptability and Feasibility of a Preoperative Very Low Calorie Diet Intervention on Surgical Weight Loss Outcomes (SAFETY) (SAFETY)

Obesity

United States
Indiana University

Completed

Very Low Calorie Diet for Diabetic Kidney Disease

Diabetic Kidney Disease

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Very Low Carbohydrate Diet as an Adjunctive Therapy for Youth Type 1 Diabetes

Type 1 Diabetes

United States
Special Hospital for Extended Treatment of Duga...
Institute for Medical Research and Occupational Health; University of Zagreb

Completed

Oxidative Stress and L-CBMN Cytome Assay in Obese After 3 Weeks VLCD

Obesity | Weight Loss | DNA Damage

Croatia
Special Hospital for Extended Treatment of Duga...
Institute for Medical Research and Occupational Health; University of Zagreb

Completed

Changes in Anthropometric, Biochemical and DNA Damage Parameters After 3-weeks VLCD in Severely Obese Patients

Obesity | Weight Loss | DNA Damage

Croatia
University of North Carolina, Chapel Hill

Completed

Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)

Diarrhea Predominant Irritable Bowel Syndrome

United States
Dr. Soetomo General Hospital

Unknown

Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer

Diet Modification | Colorectal Adenocarcinoma | Systemic Inflammation | Lactate | TNF Alpha
National Center for Research Resources (NCRR)
Duke University; Procter and Gamble; Jenny Craig, Inc.

Completed

Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
University of Pisa

Recruiting

Very Low Ketogenic Diet and Energy Expenditure

Energy Metabolism

Italy
University of Roma La Sapienza

Completed

Very Low Calories Ketogenic Diet in Migraine. (Ketomig)

Migraine | Overweight and Obesity

Italy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy

Belgium
Boehringer Ingelheim

Completed

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Healthy
University of Sao Paulo

Completed

Weight Loss Impact on Male Fertility

Obesity | Metabolic Syndrome | Sub Fertility, Male

Brazil
The University of The West Indies

Unknown

Implementation of a Very Low Calorie Diet for Remission of Type 2 Diabetes in the Community

Diabetes Mellitus Type 2 in Obese

Barbados
Boston Children's Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Brigham...

Completed

Popular Diets Study

Obesity | Insulin Resistance

United States
Lee Kirby

Completed

The Influence of Seat Height on Hemiplegic-pattern Propulsion of Manual Wheelchairs

Hemiplegia | Wheelchairs

Canada
University of Kansas Medical Center

Completed

Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults

Obstructive Sleep Apnea

United States
Norwegian University of Science and Technology
Monash University; Portuguese Research Council

Completed

Effect of Speed of Weight Loss on Compensatory Mechanisms Activated During Weight Reduction (FVS)

Obesity

Norway
Azienda Sanitaria ASL Avellino 2

Unknown

Very Low Protein Diet and Renal Death in Chronic Kidney Disease (CKD)-ERIKA Study

Chronic Renal Insufficiency

Italy
Boehringer Ingelheim

Completed

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Asthma

United States, Austria, Germany, Hungary, Slovakia, Slovenia
University of Michigan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

The Supporting Understanding of PCOS Education and Research (SUPER) Study (SUPER)

Polycystic Ovary

United States
University of Michigan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

The Lifestyle Education About Prediabetes (Leap) Study (LEAP)

PreDiabetes

United States

3

Subscribe